Table 1 Cohort characteristics. Clinical data of the 10 ART-treated participants at the time of blood collection
ART1 | ART2 | ART3 | ART4 | ART5 | ART6 | ART7 | ART8 | ART9 | ART10 | Median | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Characteristics of participants | |||||||||||
Sex | M | M | M | M | M | M | M | M | M | M | |
Age, year-range | 50-59 | 60-69 | 60-69 | 40-49 | 30-39 | 50-59 | 50-59 | 30-39 | 60-69 | 30-39 | 53.5 |
Time since diagnosis, years | 29 | 23 | 26 | 15 | 12 | 21 | 14 | 7 | 5 | 14 | 15 |
Time on antiretroviral treatment, years | 14 | 17 | 21 | 14.8 | 4 | 20 | 6 | 6.5 | 4.3 | 9 | 12 |
Time between diagnosis and ART initiation, years | 15 | 7 | 5 | 0.3 | 8 | 1 | 8 | 0.5 | 0.4 | 5 | 5 |
HIV viral load, RNA copies per ml of plasma | <40 | <40 | <40 | <40 | <40 | <40 | <40 | <40 | <40 | <40 | <40 |
CD4 cell count, cells per μL | 847 | 602 | 1076 | 625 | 471 | 911 | 836 | 461 | 624 | 882 | 731 |
CD8 cell count, cells per μL | 613 | 880 | 558 | 511 | 322 | 873 | 1551 | 941 | 545 | 1177 | 743 |
CD4/CD8 ratio | 1.4 | 0.7 | 1.9 | 1.2 | 1.5 | 1.0 | 0.5 | 0.5 | 1.1 | 0.8 | 1.1 |
Integrated HIV DNA, copies per million CD4 T cells | 403 | 1404 | 442 | 438 | 146 | 1913 | 680 | 502 | 142 | 483 | 463 |
HIV-Flow, p24+ cells per million CD4 T cells | 8 | 6 | 11 | 9 | 15 | 10 | 0 | 5 | 3 | 8 | 8 |
Assays performed | |||||||||||
Single-cell sorting assay | X | X | X | X | X | X | |||||
VLA-4 HIV DNA measures | X | X | X | X | X | X | X | X | X | ||
VLA-4 QVOA | X | X | X | X | X | X | |||||
